Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808871 · ClinicalTrials.gov registry record · Phase 2
Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)
A Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT02808871: Completed Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease, sponsored by Brigham and Women's Hospital.
NCT02808871 is a Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 20 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808871, a Phase 2 study of Rheumatoid Arthritis Interstitial Lung Disease, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
Primary Outcome
Number of participants who developed any element of the composite endpoint of decline in percent predicted FVC of 10% or greater or death.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirfenidone
Study Locations (20)
Alabama
- University of Alabama Site at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Colorado
- National Jewish Health - Denver
Florida
- University of Miami - Miami
Louisiana
- Tulane Medical Center - New Orleans
Maryland
- John Hopkins Medicine - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2021-04-07 |
| Phase | Phase 2 |
What the finished NCT02808871 record still lists
NCT02808871 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Rheumatoid Arthritis Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02808871 names 20 study sites across 20 states, led by Alabama, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02808871 about?
NCT02808871 is a clinical study titled "Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)". The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
What is the current status of trial NCT02808871?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2017-04-07. Estimated completion is 2021-04-07.
What conditions does trial NCT02808871 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis Interstitial Lung Disease.
What interventions are being tested in trial NCT02808871?
The interventions under investigation include: Placebo (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT02808871?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808871 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02808871's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI